Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apitegromab phase 3 trial in later-onset spinal muscular atrophy on nusinersen or risdiplam
2021-005314-34Phase 3Completed
- Sponsor
- Scholar Rock
- Start
- Feb 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in spinal muscular atrophy (SMA) comparing Apitegromab plus background nusinersen or risdiplam with Placebo plus background nusinersen or risdiplam (2 arms). Primary endpoint: Change from baseline in HFMSE total score at 12 months. Started Feb 2022; status: completed.
02
Drugs
apitegromab
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on 2021-005314-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005314-34.